The angiotensin II (Ang II) AT 1 -receptor antagonists, valsartan and candesartan, were compared with regard to their effect on Ang II-mediated changes in parameters of coronary endothelial function. Ang II (10 µM) induced increased concentrations of the vasoconstrictor endothelin, the procoagulatory substance plasminogenactivator-inhibitor-1 (PAI-1) and the precursor of the matrix-metalloproteinase 1 (MMP-1) in endothelial cell cultures from human coronary arteries. These increases were completely prevented by the addition of 10 µM valsartan or candesartan and partially by the addition of lower concentrations of these drugs, i.e. 1 µM and 0.1 µM. No significant difference between the effect of the two AT 1 -receptor antagonists was observed.
Introduction
The most important biological functions of angiotensin II (Ang II) are mediated by the angiotensin type 1 (AT 1 )-receptor. These actions include vasoconstriction, cell proliferation, stimulation of aldosterone release and antinatriuretic and antidiuretic effects. 1 Since Ang II is involved in the pathogenesis of hypertension, the blockade of its synthesis by angiotensin-converting enzyme inhibitors (ACE-I) or blockade of its action by AT 1receptor antagonists (ARBs) are currently favoured therapeutic options. Several ARBs with different pharmacokinetic properties are available. As yet, it is uncertain whether there are class-specific differences in the inhibitory effects on Ang IIinduced actions by these substances. Therefore, in the present experimental study we compared the effect of two widely used ARBs, valsartan and candesartan, on certain selected markers of endothelial function.As markers, the following substances were chosen: endothelin, plasminogen-activator-inhibitor-1 (PAI-1) and matrix-metalloproteinase-1 (MMP-1).
Material and methods
Ang II was purchased from Sigma Chemical Company, Munich.Valsartan and candesartan were kindly provided by Novartis, Switzerland, and Takeda, Japan, respectively. The substances were dissolved in water (Ang II) or ethanol (ARBs).The influence of angiotensin was tested at 10 µM con-centration and the ARBs were added at concentrations of 0.1, 1 and 10 µM.The most effective Ang II concentration was evaluated in preliminary experiments by testing the concentration range 0.01 µM to 10 µM.
Endothelial cells from human male coronary arteries were purchased from PromoCell, Germany, and the experiments were conducted at passages 3-4. The cells were placed in culture dishes and allowed to replicate to confluence in MCDB 131 Medium, containing 10% foetal calf serum, 20 µg/ml endothelial growth factor, 50 µg/ml heparin, 50 µg/ml penicillin, 100 µg/ml streptomycin and 2.5 µg/ml amphotericin B. Cell cultures were maintained in an atmosphere of 5% CO 2 in air.
The cells were transferred into 24-well dishes and maintained in growth medium. After confluence, a serum-free medium was substituted, the test substances were added and the cells incubated for 24 hours. Control values were determined by addition of water or ethanol alone; the final ethanol concentration per well was <1%.
Endothelin was measured directly in the cell supernatant by enzyme immuno-assay (BioTrend). The sensitivity of the assay was 10 pg/ml. Interand intra-assay variation coefficients were 9.9% and 7.1%, respectively.
PAI-1 was measured directly in the cell medium by enzyme immuno-assay (American Diagnostics). The sensitivity of the assay was 50 pg/ml. Inter-and intra-assay variation coefficients were 9.5% and 7.4%, respectively.
The zymogen pro-MMP-1 was measured directly in the supernatant by enzyme immuno-assay (R&D Diagnostics).The sensitivity of the assay was 20 pg/ml. Inter-and intra-assay variation coefficients were 10.5% and 6.9%, respectively.
Statistical analysis was performed by analysis of variance (ANOVA) and Dunnett's test from triplicates of two different experiments.
differences between the effects of the two ARBs. Figure 2 shows the changes in PAI-concentrations after addition of Ang II, with and without valsartan and candesartan. Ang II (10 µM) increased PAI-1 synthesis by 20% (CI 23;16%). Again, this increase was completely reduced to basal values by the addition of 10 µM of valsartan or candesartan and partially inhibited by the addition of 1 or 0.1 µM, respectively. No difference between the effect of the two ARBs was found, although a tendency to a stronger inhibitory effect by valsartan was observed. Figure 3 shows the changes of pro-MMP-1 concentrations after addition of Ang II, with and without valsartan and candesartan.Ang II (10 µM) increased pro-MMP-1 synthesis by 44% (CI 47;41%). For both antagonists, a concentrationdependent inhibitory effect was seen.With 10 µM valsartan or candesartan, Ang II-stimulated pro-MMP-I synthesis was reduced beyond the control value, although this was not statistically significant. No significant difference was found between the two ARBs.
Discussion
In the present in vitro experiment, Ang II increased endothelial synthesis of endothelin, PAI-1 and the precursor of the matrix-metalloproteinase 1 (MMP-1).
Endothelin is a more potent vasoconstrictor than Ang II itself and may be involved in the pathogenesis of hypertension. 2 Plasma levels of endothelin are enhanced in congestive heart failure and correlate with the severity of the disease. 2 In addition, endothelin is involved in the development of atherosclerosis by its proliferative action on smooth muscle cells. 2 PAI-1 is a procoagulatory substance, and a reduced fibrinolytic activity induced by enhanced serum concentrations of PAI-1 is considered an independent risk factor for cardiovascular diseases. 3 MMP-1 is a collagenase which has been detected in atherosclerotic plaques. 4 Enhanced synthesis of MMP-1 may contribute to plaque instability, which can lead to fatal outcomes, especially during acute coronary syndromes such as unstable angina pectoris, myocardial infarct and sudden death.
It is noteworthy that the concentrations used in the present study are in the upper pharmacological dosage range. For Ang II doses lower than 10 µM, we observed only small effects on the markers investigated. Thus, for the ARBs, higher concentrations were also required to antagonise the Ang IIinduced effects. However, higher concentrations may be required in vitro in short-term tests in which the reaction threshold can only be achieved with supra-physiological dosages. In addition, higher concentrations may be reached in vivo in the vessel wall or organs, compared with the concentrations which are usually observed in the circulation. At the dose of 10 µM, both substances exhibit affinity for the Ang II type 2 (AT 2 )-receptor, but this receptor usually is only marginally expressed in healthy human tissues. For other receptors highly expressed on the endothelium such as α 1 -, α 2 -, β 1 -receptors and others, both substances lacked any affinity at this concentration. 5, 6 The Ang II-induced activation of these endothelial markers may contribute to vasoconstriction, development of atherosclerosis and destabilisation of atherosclerotic plaques.The two ARBs, valsartan and candesartan, were equally effective in inhibit-ing the negative effects of Ang II on these markers of endothelial function. It can be assumed that there exists a class-specific mechanism of ARBs on Ang II-induced effects on endothelial function, although the role of other ARBs should also be examined. This mechanism may contribute to the prevention of the development of atherosclerosis and prevention of triggering acute coronary syndromes by ARBs.
Book review
Epstein and Brunner are to be congratulated on their timely delivery of a fairly comprehensive review of the angiotensin II (Ang II) receptor antagonists. The list of contributors is a veritable who's who in the field with only a few notable absences…..who presumably couldn't be coerced into providing a manuscript! The book reviews in depth the cell biology of angiotensin, the development of Ang II (AT 1 ) antagonists and a detailed discussion of their molecular pharmacology. The effects of the antagonists on various tissues and organs are discussed in detail, along with interactions with vasoactive factors and other hormonal systems.
The clinical development of the programme for the Ang II (AT 1 )-receptor antagonists are broadly covered with emphasis on hypertension, congestive cardiac failure and diabetes and the book concludes with a review of on-going outcome trials with this class of drug.
The work is nicely presented with clear graphics and comprehensive referencing.
Verdict -a must for anyone with a serious interest in the field
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